Last $191.90 USD
Change Today +2.69 / 1.42%
Volume 656.1K
ILMN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Frankfurt
As of 8:10 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

illumina inc (ILMN) Snapshot

Open
$189.20
Previous Close
$189.21
Day High
$192.13
Day Low
$187.01
52 Week High
10/31/14 - $197.37
52 Week Low
12/4/13 - $96.51
Market Cap
27.2B
Average Volume 10 Days
1.1M
EPS TTM
$1.99
Shares Outstanding
142.0M
EX-Date
--
P/E TM
96.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for ILLUMINA INC (ILMN)

illumina inc (ILMN) Details

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The company’s products include sequencing platforms that are based on its SBS technology are designed to meet the various demands of a range of sequencing applications; and array platforms consist of HiScan and iScan systems that are array scanners, which support the imaging of array-based genetic analysis products. It also offers various sample preparation and sequencing kits to simplify workflows and accelerate analysis. In addition, the company provides genotyping and whole genome sequencing services. It serves genomic research centers, academic institutions, government laboratories, hospitals, and reference laboratories, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic, and consumer genomics companies. The company sells its products directly, as well as through distributors. It has strategic partnerships with AstraZeneca PLC; Janssen Biotech, Inc.; and Sanofi to focus on the transition from single-analyte companion diagnostics to panel-based assays that select for companion therapeutics. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.

3,000 Employees
Last Reported Date: 02/18/14
Founded in 1998

illumina inc (ILMN) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $1.1M
President and Director
Total Annual Compensation: $153.5K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $447.7K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $457.1K
Senior Vice President of Corporate Developmen...
Total Annual Compensation: $449.6K
Compensation as of Fiscal Year 2013.

illumina inc (ILMN) Key Developments

HTG Announces Completion of IVD Development and Supply Agreement With Illumina

HTG Molecular Diagnostics Inc. announced that it entered into an agreement with Illumina Inc., under which HTG will have the right to develop certain in-vitro diagnostic (IVD) test kits that utilize Illumina sequencing technology.

Illumina Inc. Announces Unaudited Consolidated Financial Results for the Third Quarter and Nine Months Ended September 28, 2014; Revised Earnings Guidance for the Fiscal Year 2014

Illumina Inc. announced unaudited consolidated financial results for the third quarter and nine months ended September 28, 2014. For the third quarter, the company reported total revenue of $480,630,000 against $356,800,000 a year ago. Income from operations was $119,493,000 against $45,464,000 a year ago. Income before income taxes was $112,443,000 against $37,147,000 a year ago. Net income was $93,489,000 or $0.63 diluted per share against $31,357,000 or $0.22 diluted per share a year ago. Net cash provided by operating activities was $145,605,000 against $83,136,000 a year ago. Purchases of property and equipment was $28,828,000 against $18,930,000 a year ago. Free cash flow was $116,777,000 against $64,206,000 a year ago. Non-GAAP net income was $113,651,000 against $62,846,000 a year ago. Non-GAAP diluted per share was $0.77 against $0.45 per share a year ago. Non-GAAP operating profit was $190,584,000 against $115,585,000 a year ago. For the nine months, the company reported total revenue of $1,348,979,000 against $1,033,852,000 a year ago. Income from operations was $311,828,000 against $60,323,000 a year ago. Income before income taxes was $256,697,000 against $38,945,000 a year ago. Net income was $200,071,000 or $1.34 diluted per share against $44,647,000 or $0.32 diluted per share a year ago. Net cash provided by operating activities was $360,722,000 against $259,582,000 a year ago. Purchases of property and equipment was $71,164,000 against $51,905,000 a year ago. Free cash flow was $289,558,000 against $207,677,000 a year ago. Non-GAAP net income was $278,268,000 against $185,159,000 a year ago. Non-GAAP diluted per share was $1.87 against $1.35 per share a year ago. Non-GAAP operating profit was $493,285,000 against $337,311,000 a year ago. For fiscal 2014, the company expects non-GAAP diluted net income per share in the range of $2.63 to $2.65, higher than its prior guidance of $2.26 to $2.28 and GAAP diluted net income per share in the range of $1.97 to $1.99. Given results have updated guidance for 2014. The company now project revenue growth of approximately 30% year-over-year compared to the previous guidance of 25% to 26% growth. Modeling considerations include full year weighted average non-GAAP diluted shares outstanding of 149 million and a full year pro forma tax rate of 26%, which takes into account the impact of the 2014 federal R&D tax credit and other tax extenders that have yet to be enacted. If the tax credit and other extend as in past, annual tax rate would increase by approximately 200 basis points. Excluding the impact of discrete items in third quarter, 2014, previously mentioned, a more normalized tax rate for the year is 29%, slightly better than prediction coming into the year due to employees stock activity resulting in higher deductions.

Illumina, Inc. Launches New Reagent Kits for the HiSeq X(TM) Ten and HiSeq(R) 2500 Sequencing Systems

Illumina Inc. announced the launch of new reagent kits for the HiSeq X(TM) Ten and HiSeq(R) 2500 Sequencing Systems, bringing further advancements to the most comprehensive next-generation sequencing portfolio. The kits advance the proven Illumina sequencing by synthesis (SBS) chemistry and boost the power and efficiency of HiSeq Systems. The reagent kits expand the range of possibilities available to researchers using Illumina sequencing technologies by offering superior data quality on the HiSeq X Ten System and longer read lengths on the HiSeq 2500 System. For HiSeq X Ten Systems, the HiSeq X HD v2 Reagent Kit adds flexibility to population-scale human whole-genome sequencing by supporting an expanded menu of library preparation options while offering superior data quality and coverage. The HiSeq X Ten System now supports the TruSeq(R) DNA PCR-Free Sample Preparation Kit, which eliminates amplification during library preparation for industry-best coverage of challenging genomic regions with a shortened gel-free workflow. The system continues to support the TruSeq(R) Nano DNA Sample Preparation Kit, for efficient sequencing of samples with limited available DNA. Together, the reagent kits and library preparation options deliver exceptional genome coverage enabling highly accurate and comprehensive variant calling while continuing to offer human whole-genome sequencing at the $1,000 price point, including instrument depreciation. For HiSeq 2500 Systems, the HiSeq Rapid v2 Reagent Kit allows the generation of 2x250 base pair, paired-end reads and delivers up to 300 gigabases of data in 60 hours using rapid run mode. The expanded read lengths provide researchers with the ability to more accurately identify gene fusions and tackle more complex metagenomics, and de novo assembly projects. Building on the production power of the HiSeq 2500 System, the new reagents further increase the range of sequencing applications available on the platform and create opportunities for innovative studies in agrigenomics, microbial genomics, cancer genomics, and other areas. The enhancements will work on all HiSeq 2500, HiSeq 1500 and upgraded systems. The HiSeq X HD v2 Reagent Kits and the HiSeq Rapid v2 Reagent Kits will begin shipping in November 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ILMN:US $191.90 USD +2.69

ILMN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Avago Technologies Ltd $93.78 USD +2.63
Becton Dickinson and Co $141.26 USD +6.53
Dr Reddy's Laboratories Ltd 3,611 INR +35.65
Sigma-Aldrich Corp $136.53 USD -0.02
Waters Corp $115.87 USD +0.06
View Industry Companies
 

Industry Analysis

ILMN

Industry Average

Valuation ILMN Industry Range
Price/Earnings 99.6x
Price/Sales 15.4x
Price/Book 21.1x
Price/Cash Flow 84.3x
TEV/Sales 14.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ILLUMINA INC, please visit www.illumina.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.